Settimio Pacelli

PLOS ONE, Aug 2023 The skeletal muscles of Type II diabetic (T2D) patients can be characterized by a reduced vessel density, corresponding to deficiencies in microvascular angiogenesis. Interestingly, T2D also inhibits the function of many myogenic cells resident within skeletal muscle, including satellite cells, which are well-known for the role they play in maintaining homeostasis.

Comparison between the angiogenic potential of human MPCs’ secretome derived from control and diabetic MPCs Analogous to the experiments with r-Control and r-Db MPCs, whether a decline in angiogenesis could also be observed in diabetic muscle precursor cells (MPCs) derived from a human source was evaluated. Specifically, myoblasts were purchased, and experiments similar to that described above were carried out, i.e..

Secretome-based therapies have the potential to become the next generation of viable therapeutic wound repair treatments. However, precise strategies aimed to refine and control the secretome composition are necessary to enhance its therapeutic efficacy and facilitate clinical translation. In this study, we aim to accomplish this by transfecting human adipose-derived stem cells (hASCs) with microRNA-146a, which is a potent regulator of angiogenesis and inflammation.